Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lessened its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 14.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,200,797 shares of the medical device company’s stock after selling 376,945 shares during the period. Janus Henderson Group PLC owned approximately 3.41% of Tandem Diabetes Care worth $77,930,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TNDM. MCF Advisors LLC grew its position in Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after purchasing an additional 445 shares during the last quarter. Van ECK Associates Corp increased its position in Tandem Diabetes Care by 8.6% in the 4th quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock valued at $175,000 after acquiring an additional 467 shares during the period. Texas Permanent School Fund Corp raised its stake in Tandem Diabetes Care by 1.6% during the 1st quarter. Texas Permanent School Fund Corp now owns 56,910 shares of the medical device company’s stock valued at $2,015,000 after acquiring an additional 915 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Tandem Diabetes Care in the first quarter worth $35,000. Finally, Arcadia Investment Management Corp MI increased its holdings in shares of Tandem Diabetes Care by 141.6% during the first quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock valued at $66,000 after purchasing an additional 1,085 shares during the period.

Tandem Diabetes Care Stock Up 3.5 %

Shares of TNDM traded up $1.26 during trading hours on Wednesday, hitting $37.63. 361,784 shares of the company were exchanged, compared to its average volume of 1,694,109. Tandem Diabetes Care, Inc. has a 52 week low of $13.82 and a 52 week high of $53.69. The company has a debt-to-equity ratio of 1.43, a quick ratio of 3.01 and a current ratio of 3.81. The firm’s 50 day moving average is $44.95 and its 200-day moving average is $36.10.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, May 2nd. The medical device company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17. The business had revenue of $191.67 million for the quarter, compared to analyst estimates of $173.06 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. As a group, equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.71 EPS for the current year.

Insider Buying and Selling at Tandem Diabetes Care

In related news, Director Dick Allen sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $51.68, for a total transaction of $258,400.00. Following the transaction, the director now owns 24,396 shares in the company, valued at approximately $1,260,785.28. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TNDM. Lake Street Capital increased their target price on shares of Tandem Diabetes Care from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, May 22nd. Oppenheimer raised their price objective on shares of Tandem Diabetes Care from $47.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, June 10th. Wells Fargo & Company upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $21.00 to $45.00 in a research report on Monday, April 29th. Leerink Partnrs upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 25th. Finally, Stifel Nicolaus boosted their price objective on Tandem Diabetes Care from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.25.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.